There's no evidence to suggest separating the vaccine makes the shot safer or more effective.

October 6, 2025 Check out STAT+

Sponsored By

Jan Sonnenmair/Getty Images Acting CDC director calls for MMR vaccine to be broken up into three shots Jim O'Neill didn't say why he wants to break up the MMR shot, and there's no evidence that doing so would make the immunization safer or more effective. By Anil Oza 2025 Nobel Prize in medicine goes to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for immune system discoveries Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi are the new Nobel laureates, winning the 2025 prize in physiology or medicine By Andrew Joseph CDC approves updated Covid-19, chickenpox vaccine recommendations Move clears the way for kids in low-income families to get access to Covid shots. A delay had previously blocked some shipments of shots. By Anil Oza and Chelsea Cirruzzo Thumỹ Phan for STAT STAT+ | From erectile dysfunction to weight loss, how telehealth got hooked on drug-first thinking Telehealth began as a way to help patients access doctors, but has rapidly transformed into a way to help companies sell drugs. A STAT special report by Katie Palmer. By Katie Palmer How this week's Supreme Court case on conversion therapy could impact the regulation of medicine Supreme Court will hear a challenge to Colorado's ban on conversion therapy, which could have large consequences for regulation of medicine By Theresa Gaffney STAT+ | With much to win (or lose), drugmakers and European officials bear down on major policy overhaul Proposals have far-reaching implications for patients' access to medicines and the pharma industry's bottom lines. By Andrew Joseph Patrick Semansky/AP Opinion: The NIH ordered me to stop my 'dangerous' gain-of-function research. It isn't dangerous at all Gain-of-function experiments have been crucial for increasing our understanding of bacteria in the pursuit of discovering new treatments. By Sarah Stanley Opinion: Onshoring could threaten the resilient supply chain for biosimilars and generics Generics and biosimilars are already operating their manufacturing and supply chains to maximum efficiency with very thin margins. Onshoring threatens this. By Gillian Woollett

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser